171 related articles for article (PubMed ID: 28671062)
1. A 12-week dose-escalating study of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese hemodialysis patients
.
Yokoyama K; Fukagawa M; Shigematsu T; Akiba T; Fujii A; Odani M; Akizawa T
Clin Nephrol; 2017 Aug; 88(2):68-78. PubMed ID: 28671062
[TBL] [Abstract][Full Text] [Related]
2. A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients.
Fukagawa M; Yokoyama K; Shigematsu T; Akiba T; Fujii A; Kuramoto T; Odani M; Akizawa T;
Nephrol Dial Transplant; 2017 Oct; 32(10):1723-1730. PubMed ID: 28057872
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism.
Shigematsu T; Fukagawa M; Yokoyama K; Akiba T; Fujii A; Odani M; Akizawa T;
Clin Exp Nephrol; 2018 Apr; 22(2):426-436. PubMed ID: 28836058
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of Parsabiv
Harada K; Fujioka A; Konno M; Inoue A; Yamada H; Hirota Y
Eur J Pharmacol; 2019 Jan; 842():139-145. PubMed ID: 30342948
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan.
Yokoyama K; Fukagawa M; Shigematsu T; Akiba T; Yoshikawa K; Tsuchiya A; Kuwabara M; Akizawa T
Clin Exp Nephrol; 2021 Jan; 25(1):66-79. PubMed ID: 32816132
[TBL] [Abstract][Full Text] [Related]
6. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
[TBL] [Abstract][Full Text] [Related]
7. Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.
Li X; Yu L; Asuncion F; Grisanti M; Alexander S; Hensley K; Han CY; Niu QT; Dwyer D; Villasenor K; Stolina M; Dean C; Ominsky MS; Ke HZ; Tomlinson JE; Richards WG
Bone; 2017 Dec; 105():163-172. PubMed ID: 28867373
[TBL] [Abstract][Full Text] [Related]
8. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.
Block GA; Bushinsky DA; Cunningham J; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Mix TC; Moe SM; Patel UD; Silver J; Spiegel DM; Sterling L; Walsh L; Chertow GM
JAMA; 2017 Jan; 317(2):146-155. PubMed ID: 28097355
[TBL] [Abstract][Full Text] [Related]
9. Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects.
Martin KJ; Bell G; Pickthorn K; Huang S; Vick A; Hodsman P; Peacock M
Nephrol Dial Transplant; 2014 Feb; 29(2):385-92. PubMed ID: 24235081
[TBL] [Abstract][Full Text] [Related]
10. Improved Control of Secondary Hyperparathyroidism in Hemodialysis Patients Switching from Oral Cinacalcet to Intravenous Etelcalcetide, Especially in Nonadherent Patients.
Xipell M; Montagud-Marrahi E; Rubio MV; Ojeda R; Arias-Guillén M; Fontseré N; Rodas L; Vera M; Broseta JJ; Torregrosa V; Filella X; Maduell F
Blood Purif; 2019; 48(2):106-114. PubMed ID: 30699421
[TBL] [Abstract][Full Text] [Related]
11. Treatment of secondary hyperparathyroidism in patients on hemodialysis using a novel synthetic peptide calcimimetic, etelcalcetide: a short-term clinical study.
Mima A; Tansho K; Nagahara D; Watase K
J Int Med Res; 2018 Nov; 46(11):4578-4585. PubMed ID: 30027791
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients.
Bell G; Huang S; Martin KJ; Block GA
Curr Med Res Opin; 2015 May; 31(5):943-52. PubMed ID: 25786369
[TBL] [Abstract][Full Text] [Related]
13. Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study.
Shigematsu T; Fukagawa M; Yokoyama K; Akiba T; Fujii A; Odani M; Akizawa T
Clin Ther; 2018 Dec; 40(12):2099-2111. PubMed ID: 30473399
[TBL] [Abstract][Full Text] [Related]
14. An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism.
Block GA; Chertow GM; Sullivan JT; Deng H; Mather O; Tomlin H; Serenko M
PLoS One; 2019; 14(3):e0213774. PubMed ID: 30875390
[TBL] [Abstract][Full Text] [Related]
15. Influence of dialysate Ca concentrations on the therapeutic effects of etelcalcetide with concomitant drugs in patients with secondary hyperparathyroidism.
Shigematsu T; Fukagawa M; Yokoyama K; Akiba T; Fujii A; Shinoda A; Akizawa T
Nephrology (Carlton); 2020 Aug; 25(8):634-643. PubMed ID: 31765028
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients.
Shigematsu T; Shimazaki R; Fukagawa M; Akizawa T;
Clin Exp Nephrol; 2019 Feb; 23(2):258-267. PubMed ID: 30159688
[TBL] [Abstract][Full Text] [Related]
17. One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism.
Bushinsky DA; Chertow GM; Cheng S; Deng H; Kopyt N; Martin KJ; Rastogi A; Ureña-Torres P; Vervloet M; Block GA
Nephrol Dial Transplant; 2020 Oct; 35(10):1769-1778. PubMed ID: 30859218
[TBL] [Abstract][Full Text] [Related]
18. Phase 1, single-dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of etelcalcetide in pediatric patients with secondary hyperparathyroidism receiving hemodialysis.
Sohn W; Salusky IB; Schmitt CP; Taylan C; Walle JV; Ngang J; Yan L; Kroenke M; Warady BA
Pediatr Nephrol; 2021 Jan; 36(1):133-142. PubMed ID: 32647975
[TBL] [Abstract][Full Text] [Related]
19. A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism.
Yokoyama K; Fukagawa M; Shigematsu T; Akiba T; Fujii A; Yamauchi A; Odani M; Akizawa T;
Kidney Int Rep; 2017 Jul; 2(4):634-644. PubMed ID: 29142982
[TBL] [Abstract][Full Text] [Related]
20. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
